REPOSITIVE LIMITED: INTERNATIONAL DEVELOPMENT PROGRAMME TO INCREASE THE IMPACT OUR ONLINE PLATFORM FOR QUERYING AND ACCESS TO MOLECULAR DATA ON PATIENT DERIVED XENOGRAFT MODELS.

点击翻译按钮获取中文摘要

Patient derived xenograft (PDX) models are powerful tools used by scientists studying cancer and indiscovery of new cancer treatments. Each one is grown from a sample of a cancerous tumour donated by acancer sufferer: so they are precious, valuable and useful. But scientists find it hard to find suitable onesfor their work and so many spend a lot of time testing them, just to collect the same basic information overand over again. Repositive is creating an online platform for scientists to find PDX models and data tomake sure that they are the best ones for their work. This project, costing £29,968 and lasting 3 months,funds us build the platform with the help of PDX model providers and pharmaceutical companies who usethem often, and who will give us feedback on our concepts and designs. It will save 3 months ofdevelopment time and will enable us to make sure that they find the platform valuable and use it when itis completed. In future it will help companies to save up to 6 months in drug discovery time, so that newtreatments can be identified and brought to market more quickly and at lower cost than now.